Refractory Central Nervous System Lymphoma
5 clinical trials · Condition
◉ Watch Refractory Central Nervous System Lymphoma
| Record | Firm | Date |
|---|---|---|
| A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma (NCT04845139) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-07-02 |
| Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma (NCT03770416) | M.D. Anderson Cancer Center | 2019-02-15 |
| Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma (NCT03558750) | Vanderbilt-Ingram Cancer Center | 2018-06-14 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729) | Fred Hutchinson Cancer Center | 2017-12-05 |
Track Refractory Central Nervous System Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.